Request Case Review
Ruijin Hospital上海交通大学医学院附属瑞金医院
Small avatar-style portrait shown on Li Junmin's Haodf profile.
Department of Hematology

Li Junmin

李军民

Chief Physician, Doctoral Supervisor, Deputy Director of Hematology, and Deputy Director of the Shanghai Institute of Hematology

Ruijin Hospital上海交通大学医学院附属瑞金医院· Shanghai

Areas of Expertise

Hematologic malignancies including acute promyelocytic leukemiaAcute myeloid leukemiaLymphomaMultiple myelomaAdditional work in hematologic immunology and cellular immunotherapy
Request Consultation with Junmin

Professional Biography

Dr. Li Junmin is Chief Physician, Doctoral Supervisor, Deputy Director of Hematology, and Deputy Director of the Shanghai Institute of Hematology at Ruijin Hospital, Shanghai. Junmin specializes in Hematologic malignancies including acute promyelocytic leukemia, acute myeloid leukemia, lymphoma, and multiple myeloma, with additional work in hematologic immunology and cellular immunotherapy.

Education & Training

  • Suzhou Medical College (1987)
  • Master's degree in Hematology, Shanghai Second Medical University
  • Paris Institute of Hematology and Vascular Diseases — Advanced study in hematology (France)

Notable Publications

Cellular hierarchy insights reveal leukemic stem-like cells and early death risk in acute promyelocytic leukemia.

Nature Communications (2024) — co-author

PubMed/DOI

Interplay between hypertriglyceridemia and acute promyelocytic leukemia mediated by the cooperation of peroxisome proliferator-activated receptor-α with the PML/RAR α fusion protein on super-enhancers.

Haematologica (2022) — co-author

PubMed/DOI

Leadership & Positions

  • Deputy Director, Department of Hematology, Ruijin Hospital
  • Deputy Director, Shanghai Institute of Hematology
  • Vice President, Ruijin Hospital Wuxi Branch

Pioneering Contributions

1

As a senior Ruijin Hospital hematologist and deputy director of the Shanghai Institute of Hematology, Li Junmin is part of the institutional lineage that developed and extended the internationally recognized APL treatment approach known as the 'Shanghai Protocol'.

2

His publication record shows sustained contributions to modern APL work at Ruijin, including prognostic modeling, metabolic biology, leukemic stem-like cell analysis, and early-death risk stratification in acute promyelocytic leukemia.

3

Secondary professional profiles state that he participated in drafting Chinese clinical treatment guidelines for acute promyelocytic leukemia, linking his work to the translation of Ruijin's APL experience into broader clinical practice.

International Patient Services

Full support for your journey to China

Medipath provides comprehensive support for international patients. Services include full English-speaking medical consultations, dedicated medical translation staff, and specialized assistance with medical visa applications to ensure a seamless healthcare journey.

English Consultations

Full English-speaking medical appointments

Medical Translation

Dedicated translation for all documentation

Visa Assistance

Medical visa application support